Evidence map›Paper›PMID 42746569›Full record

ArticleDrug design, development and therapy2026

Study on Baicalin Treatment of

Yin Liqiao, Sun Yi, Zhang Haifeng, Ma Hongfei, Ge Xuelin, Liang Shuang, Wang Ping, Chen Jin, Fang Fang, Wang Weiming and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Yin Liqiao *Institute of Traditional Chinese Medicine, Heilongjiang Academy of Chinese Medicine Sciences, Harbin, People's Republic of China.
Sun Yi *Institute of Traditional Chinese Medicine, Heilongjiang Academy of Chinese Medicine Sciences, Harbin, People's Republic of China.
Zhang HaifengInstitute of Traditional Chinese Medicine, Heilongjiang Academy of Chinese Medicine Sciences, Harbin, People's Republic of China.
Ma HongfeiInstitute of Traditional Chinese Medicine, Heilongjiang Academy of Chinese Medicine Sciences, Harbin, People's Republic of China.
Ge XuelinInstitute of Traditional Chinese Medicine, Heilongjiang Academy of Chinese Medicine Sciences, Harbin, People's Republic of China.
Liang ShuangInstitute of Traditional Chinese Medicine, Heilongjiang Academy of Chinese Medicine Sciences, Harbin, People's Republic of China.
Wang PingInstitute of Traditional Chinese Medicine, Heilongjiang Academy of Chinese Medicine Sciences, Harbin, People's Republic of China.
Chen JinInstitute of Traditional Chinese Medicine, Heilongjiang Academy of Chinese Medicine Sciences, Harbin, People's Republic of China.
Fang FangDepartment of Academic Theoretical Research, Heilongjiang University of Chinese Medicine, Harbin, People's Republic of China.
Wang WeimingInstitute of Traditional Chinese Medicine, Heilongjiang Academy of Chinese Medicine Sciences, Harbin, People's Republic of China.
Meng YanliInstitute of Traditional Chinese Medicine, Heilongjiang Academy of Chinese Medicine Sciences, Harbin, People's Republic of China.
Tang GuixinAdvanced Microscopy and Instrumentation Research Center, Harbin Institute of Technology, Harbin, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Baicalin is an ingredient of Qinbai Qingfei concentrated pills that is first new traditional Chinese medicine proved by SFDA for the treatment of Methods: The recombinant plasmid pET28α- CARDs TX D1 was transferred into Results: The researchers obtained purified CARDs TX D1 protein. Biacore verified a good combination Baicalin and D1 protein. Immunohistochemistry results showed that the expression of FAS, FADD, and LTB4R was reduced in Baicalin compared with the model control group and ELISA results showed that the Baicalin reduced expression of the TNF-α, Caspase-3 compared with the model group. PCR results showed that the mRNA expression of FAS, FASL, LTB4R1, and Caspase-3 was significantly reduced in Baicalin compared with the model control group ( Conclusion: Baicalin can improve experimental

Indexed as

Anti-Bacterial AgentsBacterial ProteinsFlavonoidsMycoplasma pneumoniaePneumonia, MycoplasmaApoptosisDose-Response Relationship, DrugHumansStructure-Activity RelationshipAnti-Bacterial AgentsBacterial ProteinsbaicalinFlavonoidsADP-ribosyltransferaseBaicalinCARDs TX D1 proteinMycoplasma pneumoniae pneumoniaQinbai Qingfei concentrated pills

Identifiers

PMID42746569
PMCPMC13576847

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.